ESMO 2017: Medical Costs and Health Care Resource Use in Elderly US Patients With Newly Diagnosed Metastatic or Surgically Unresectable Urothelial Carcinoma Using Surveillance, Epidemiology, and End Results (SEER) Medicare Data

Madrid, Spain (UroToday.com) Dr. Aly and colleagues presented their results of medical costs and health care use among elderly patients with metastatic urothelial carcinoma at today’s poster session at ESMO 2017. Most elderly metastatic urothelial carcinoma patients receive platinum-based therapy as first line of treatment but invariably progress, requiring additional lines of treatment and health care resource use. The objective of this study was to estimate medical costs and health care resource use associated with each line of treatment in US elderly patients with metastatic urothelial carcinoma.

ESMO 2017: Real World Treatment Costs and Resource Utilization among Patients with Metastatic Bladder Cancer

Madrid, Spain (UroToday.com) First-line cisplatin, followed by second-line taxane or other systemic chemotherapy, has been the historic standard of care for patients with metastatic bladder cancer. However, there is a paucity of literature regarding longitudinal costs and resources consumed during the treatment of metastatic bladder cancer patient. The objective of this study was to investigate drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.

ESMO 2017: Comparison of tumor mutational burden in relevant molecular subsets of metastatic urothelial cancer 

Madrid, Spain (UroToday.com)  Dr. Sumanta Pal and colleagues presented their study assessing tumor mutational burden in molecular subsets of metastatic urothelial carcinoma at ESMO 2017.  Previous phase I and II studies suggest a potential benefit with targeted therapy (e.g., FGFR3, ERBB2/3 and CDK4/6 inhibitors) in certain molecular subsets of metastatic urothelial carcinoma. Combined with increasing data supporting PD-1/PD-L1 inhibitors in metastatic urothelial carcinoma, there is interest in combining targeted therapy and immunotherapy agents. Since tumor mutation burden is a putative biomarker of immunotherapy response [1], the objective of this study was to investigate differences in tumor mutation burden in relevant molecular subsets of metastatic urothelial carcinoma.

ESMO 2017: Will RANGE study impact the standard of care in metastatic urothelial carcinoma?

Madrid, Spain (UroToday.com) Dr. Yohann Loriot provided an in depth and high-level discussant commentary for the late-breaking abstract “RANGE: A randomized, double-blind, placebo controlled phase 3 study of docetaxel with or without ramucirumab in platinum refractory advanced or metastatic urothelial carcinoma” [1] presented by Dr. Petrylak and colleagues. 

ESMO 2017: A Phase III, Randomized, Double-Blind, Multicenter Study of Adjuvant Nivolumab vs Placebo in Patients with High-Risk Invasive Urothelial Carcinoma (CheckMate 274)

Madrid, Spain (UroToday.com) Dr. Bajorin and colleagues presented their phase III trial design assessing adjuvant nivolumab vs placebo in patients with high risk invasive urothelial carcinoma. Standard of care for muscle-invasive bladder cancer is cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy + pelvic node dissection or cystectomy + pelvic node dissection alone if cisplatin-ineligible.

ESMO 2017: Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial

Madrid, Spain (UroToday.com) Dr. Thomas Powles and his international colleagues presented their trial design for KEYNOTE-361, a phase III trial assessing pembrolizumab +/- chemotherapy vs chemotherapy for patients with advanced urothelial cancer.

ESMO 2017: RANGE: A randomized, double-blind, placebo controlled phase 3 study of docetaxel with or without ramucirumab in platinum refractory advanced or metastatic urothelial carcinoma

Madrid, Spain (UroToday.com) Dr. Petrylak and colleagues presented findings from their phase III randomized controlled trial assessing docetaxel with or without ramucirumab in platinum refractory advanced or metastatic urothelial carcinoma. As we know, limited treatment options are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma.
Page 2 of 3
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe